Search - Université de Rennes Access content directly

Filter your results

12 Results
Author: personID (integer) : 975639
Image document

Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial

Vincent Ribrag , Serge Koscielny , Jacques Bosq , Thibaut Leguay , Olivier Casasnovas et al.
The Lancet, 2016, 387 (10036), pp.2402 - 2411. ⟨10.1016/S0140-6736(15)01317-3⟩
Journal articles inserm-01419476v1

Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS.

Arnaud Pigneux , Jean-Luc Harousseau , Francis Witz , Mathieu Sauvezie , Marie-Christine Bene et al.
Journal of Clinical Oncology, 2010, 28 (18), pp.3028-34. ⟨10.1200/JCO.2009.26.4648⟩
Journal articles hal-00849638v1

Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group

Thorsten Braun , Sophie Cereja , Sylvie Chevret , Emmanuel Raffoux , Marie Beaumont et al.
Cancer, 2015, 121 (14), pp.2393-2399. ⟨10.1002/cncr.29389⟩
Journal articles hal-01237097v1
Image document

How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?

Francine Garnache-Ottou , Chrystelle Vidal , Sabeha Biichlé , Florian Renosi , Eve Poret et al.
Blood Advances, 2019, 3 (24), pp.4238-4251. ⟨10.1182/bloodadvances.2019000647⟩
Journal articles hal-02442440v1

Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial

Anne Bouvier , Jean-Francois Hamel , Jacques Delaunay , Eric Delabesse , Pierre-Yves Dumas et al.
European Journal of Haematology, 2021, 107 (1), pp.111-121. ⟨10.1111/ejh.13626⟩
Journal articles hal-03604930v1

Is Arsenic Trioxide (ATO) Required in the Treatment of Standard Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL 2006) By the French Belgian Swiss APL Group

Lionel Adès , Xavier Thomas , Agnes Cuerci-Bres , Raffoux Emmanuel , Olivier Spertini et al.
Blood, 2015, 126 (23), pp.451
Journal articles hal-01300812v1
Image document

Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study

Élie Azoulay , Pedro Castro , Adel Maamar , Victoria Metaxa , Alice Gallo de Moraes et al.
The Lancet Haematology, 2021, 8 (5), pp.e355-e364. ⟨10.1016/S2352-3026(21)00060-0⟩
Journal articles hal-03208127v1
Image document

Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial

Mathilde Hunault-Berger , N. Maillard , C. Himberlin , C. Recher , Aline Schmidt-Tanguy et al.
Blood Cancer Journal, 2017, 7 (6), pp.e568. ⟨10.1038/bcj.2017.50⟩
Journal articles inserm-01814864v1

Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemia

Xavier Cahu , Martin Carré , Christian Recher , Arnaud Pigneux , Mathilde Hunault-Berger et al.
European Journal of Haematology, 2017, 98, pp.443-449. ⟨10.1111/ejh.12850⟩
Journal articles hal-01558818v1

Addition of Lomustine (CCNU) to Induction and Post-Remission Chemotherapy for Fit Elderly AML Patients without Unfavorable Cytogenetics: Results of the Lamsa-2007 Goelams Trial

Arnaud Pigneux , Christian Récher , Marie C. Bene , Julien Asselineau , Ariane C. Mineur et al.
Blood, 2015, 126 (23)
Journal articles hal-01295674v1
Image document

Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study

Laetitia Largeaud , Pascale Cornillet-Lefebvre , Jean-François Hamel , Pierre-Yves Dumas , Naïs Prade et al.
Leukemia, 2021, 35 (5), pp.1291-1300. ⟨10.1038/s41375-020-01031-1⟩
Journal articles hal-03623649v1

Induction-related cost of patients with acute myeloid leukaemia in France.

Virginie Nerich , Bruno Lioure , Maryline Rave , Christian Recher , Arnaud Pigneux et al.
Int J Clin Pharm, 2011, 33 (2), pp.191-9. ⟨10.1007/s11096-010-9462-1⟩
Journal articles istex hal-00849659v1